Cargando…

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

BACKGROUND: Ovarian cancer is a fatal gynecological malignancy. The resistance to chemotherapy in ovarian cancer treatment has been a thorny issue. This study is aimed at probing the molecular mechanism of cisplatin (DDP) resistance in ovarian cancer. METHODS: Bioinformatics analysis was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Weijia, Zhao, Xibo, Zhang, Rujian, Xie, Jiabin, Zhang, Guangmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256449/ https://www.ncbi.nlm.nih.gov/pubmed/37304662 http://dx.doi.org/10.1155/2023/7700673

Ejemplares similares

Circular RNA CDR1as Alleviates Cisplatin-Based Chemoresistance by Suppressing MiR-1299 in Ovarian Cancer
por: Wu, Han, et al.
Publicado: (2022)

Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis
por: Abdullah, Nada, et al.
Publicado: (2021)

LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
por: Ren, Niansheng, et al.
Publicado: (2020)

Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer
por: Zhang, P, et al.
Publicado: (2014)

Adrenomedullin induces cisplatin chemoresistance in ovarian cancer through reprogramming of glucose metabolism
por: Dou, Lei, et al.
Publicado: (2023)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C E, et al.
Publicado: (2016)

VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer
por: Ning, Yingxia, et al.
Publicado: (2021)

Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer
por: Zhao, Xibo, et al.
Publicado: (2021)

Immune Characterization of Ovarian Cancer Reveals New Cell Subtypes With Different Prognoses, Immune Risks, and Molecular Mechanisms
por: Cong, Shanshan, et al.
Publicado: (2020)

FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer
por: Zhu, Wei, et al.
Publicado: (2023)

PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation
por: Kobayashi, Noriko, et al.
Publicado: (2013)

The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis
por: Farrand, Lee, et al.
Publicado: (2014)

Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin
por: Javanmardi, Sanaz, et al.
Publicado: (2020)

Mitochondrial Dynamics Mediated by DRP1 and MFN2 Contributes to Cisplatin Chemoresistance in Human Ovarian Cancer SKOV3 cells
por: Zou, Guang-Ping, et al.
Publicado: (2021)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer
por: Ruan, Xiaohong, et al.
Publicado: (2019)

Apigenin induces apoptosis and counteracts cisplatin-induced chemoresistance via Mcl-1 in ovarian cancer cells
por: Qi, Yuyan, et al.
Publicado: (2020)

Cisplatin-Resistant Gastric Cancer Cells Promote the Chemoresistance of Cisplatin-Sensitive Cells via the Exosomal RPS3-Mediated PI3K-Akt-Cofilin-1 Signaling Axis
por: Sun, Meng-Yao, et al.
Publicado: (2021)

MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2
por: Zhao, Henan, et al.
Publicado: (2016)

Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance
por: Shang, Chao, et al.
Publicado: (2017)

Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
por: Wu, Yi-Hui, et al.
Publicado: (2019)

BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma
por: Gao, Wei, et al.
Publicado: (2017)

Metallothionein-3 promotes cisplatin chemoresistance remodelling in neuroblastoma
por: Rodrigo, Miguel Angel Merlos, et al.
Publicado: (2021)

Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy
por: Feldmann, Daniel P., et al.
Publicado: (2020)

Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy
por: Dong, Xuqiang, et al.
Publicado: (2016)

OIP5 Promotes Growth, Metastasis and Chemoresistance to Cisplatin in Bladder Cancer Cells
por: Wang, Dailian, et al.
Publicado: (2018)

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles
por: Xiong, Xunhao, et al.
Publicado: (2014)

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
por: Qu, Yang, et al.
Publicado: (2022)

Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance
por: Singh, Mohan, et al.
Publicado: (2013)

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
por: Bieg, Dominik, et al.
Publicado: (2018)

Correction: Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance
por: Shang, Chao, et al.
Publicado: (2022)

Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to cisplatin-induced apoptosis
por: ZHAO, ZHIFANG, et al.
Publicado: (2014)

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells
por: Huang, Ming-ju, et al.
Publicado: (2018)

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2
por: Li, Bo, et al.
Publicado: (2019)

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2019)

Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51
por: Wang, Bingliang, et al.
Publicado: (2015)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mt39n0jqu9c87842gmdmd0pvmj